.Pharmacolibrary.Drugs.D_Dermatologicals.D05A_AntipsoriaticsForTopicalUse.D05AX55_TazaroteneAndUlobetasol.TazaroteneAndUlobetasol .Pharmacolibrary.Drugs.D_Dermatologicals.D05A_AntipsoriaticsForTopicalUse.D05AX55_TazaroteneAndUlobetasol.TazaroteneAndUlobetasol| name: | TazaroteneAndUlobetasol | |
| ATC code: | D05AX55 | route: | topical |
| compartments: | 1 | |
| dosage: | 5 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | L/h |
| other parameters in model implementation | ||
Tazarotene and ulobetasol is a fixed-combination topical medication approved for the treatment of plaque psoriasis in adults. Tazarotene is a third-generation retinoid that modulates keratinocyte differentiation and proliferation, while ulobetasol is a potent topical corticosteroid with anti-inflammatory properties. The combination is used for short-term topical management of psoriasis and is currently an approved treatment in several countries.
No peer-reviewed publications currently report full pharmacokinetic models or parameters for the fixed-combination tazarotene and ulobetasol product in humans. Limited data on systemic absorption of the individual components after topical administration suggest low bioavailability, but key PK parameters are not available.